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Non-Hodgkin lymphoma (NHL) of the lip is extremely rare. It is usually indolent and in early
stages a local approach is often indicated. We present a case report of a patient with extran-
odal NHL of the lip treated with chemotherapy and low-dose radiation treatment (RT). The
patient was affected by B-cell NHL of the marginal zone, Stage IAE. After a few months of
observation with this progressive disease, the patient was submitted to two cycles of
chemotherapy with no response. Therefore, he was treated with very low-dose RT consisting
of two fractions of 2 Gy. Complete response was observed and after 1-year follow-up, persis-
tent complete response was recorded. In cases of localized disease, especially in patients with
comorbidities of poor performance status (PS), low-dose RT can be an appropriate approach
with excellent outcomes in terms of effectiveness and low risk of toxicity.
 2018 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
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Non-Hodgkin lymphoma (NHL) is very rare heterogeneous
group of lymphoproliferative disorders originating from B-
cells, T-cells, or natural-killer cells. According to estimates
of the Italian Association of Tumor Registers (AIRTUM),
every year in Italy 5,600 and 4,600 new cases of NHL are
diagnosed among men and women, respectively, while the
deaths caused by this cancer approach 2,500 patients
(equally divided between the two sexes). NHL develops
mostly in people between 50 and 60 years old and occurs
more frequently in males than females [1]. Furthermore,
the incidence of NHL has increased in the past decade,
probably attributable to human immunodeficiency virus or
Borrelia virus and to antirejection drug therapy in patients
who have undergone organ transplantation [2]. Immunose-
nescence is also considered as a potential mechanism of
lymphoma etiology.
Marginal zone lymphoma (MZL) is a group of indolent B-
cell malignancies which are thought to originate from B-
lymphocytes that are normally present in the marginal zone
of lymphoid follicles of lymph nodes, mucosal lymphoid tis-
sues, and spleen [3]. This lymphoproliferative disorder
accounts for 5–17% of all NHL cases in adults [4]. Accord-
ing to the World Health Organization classification systems,
MZL includes three subtypes depending on the site of lym-
phoma involvement: extranodal marginal zone B-cell lym-
phoma of mucosa-associated lymphoid tissue (MALT),
splenic MZL, and nodal MZL [5]. Furthermore, the neoplastic
elements share a similar immunophenotype: positivity for B-
cell markers CD19, CD20, and CD22, and negative for CD5
and CD10 [6].
The most common sites of manifestation of nongastric
MALT lymphomas are the salivary glands, thyroid, upper air-
ways, lung, ocular adnexa, breast, liver, urothelial system,
skin, dura, and other soft tissues. The development of this
neoplasm in the head and neck region, except for the sali-
vary glands, is very rare.
Besides a common cell of origin and some similarities
among them, the clinical presentation is very different,
with symptoms related to lymphoma location. MALT and
splenic MZL present an indolent disease and are associated
with long survival. Nodal MZL is a more aggressive disease
and patients have a shorter disease-free survival [7].
Indeed, in patients with nodal MZL peripheral lym-
phoadenopathy is present in nearly all cases (95%); thoracic
or abdominal lymph nodes may also be involved in 50% of
cases. Advanced-stage disease is observed in approximately
two-thirds of newly diagnosed patients with nodal MZL [8].
The optimal approach for the three subtypes has yet to
be defined; treatment options for MZLs are driven by the
site of involvement, stage, and related symptoms. Given
the frequently limited stage at presentation, antimicrobial
therapy or local approaches, such as radiation therapy
(RT), have been the mainstay of treatment; however, there
are also systemic regimens available with excellent safety
and efficacy profiles [9].
Here, we describe a rare case of MZL arising on the supe-
rior and inferior lip, treated with chemotherapy and subse-
quently very low-dose RT.Please cite this article as: B. Lavinia, S. S. Dario, P. Guido et al., Low-do
Case report and literature review, Hematol Oncol Stem Cell Ther, https:Case report
In May 2016, an 82-year-old man was referred to our hema-
tological multidisciplinary team for persistent swelling of
the lower lip in the previous few months. After a thorough
examination, biopsy of the lip was performed. Immunohis-
tochemical reactions showed diffuse infiltration of fibro-
muscular fragment by CD20+ small lymphocytes CD10
and CD5, with small accompanying CD3+ and CD5+ lym-
phocytes, and Ki-67 value of 5% (Fig. 1). Morphological
and phenotypic characteristics led to the diagnosis of B-
cell NHL of the marginal zone. B symptoms were absent.
Staging workup with computed tomography (CT) total body
scan did not reveal any other site of disease. Complete
blood cell (CBC) was normal. Bone marrow biopsy was not
performed. The patient had stage IA E disease. At the begin-
ning, no indication for cytoreductive therapy was given. A
few months after diagnosis, clinical examination was again
performed with evidence of progressive disease and a new
small lesion of the lower and upper lip, respectively.
In September 2016, the patient received chemotherapy
with 10 mg chlorambucil and 50 mg prednisone per day for
4 days. At diagnosis, the patient was not eligible for conven-
tional treatment with rituximab and chlorambucil but with
chlorambucil and prednisone, as he had received a recent
diagnosis of prostate cancer treated with hormone depriva-
tion with LH-RH analogous.
Despite the treatment with chlorambucil being well con-
ducted, the patient had a progression of local disease that
required a modification of the treatment. Therefore, many
comorbidities radiotherapy were considered.
In November, the patient was submitted to a second
course of chemotherapy which consisted of 10 mg chloram-
bucil and 25 mg prednisone for 1 week.
At the end of the planned chemotherapy, clinical exam-
ination recorded no measurable change in the lower lip
lesion (stable disease) and further progression of upper lip
disease, while restaging CT scan confirmed disease as a
localized NHL.
In December 2016, given the nonresponse to medical
therapy, the patient was referred to the Department of
Radiation Oncology of Mauriziano Hospital.
In January 2017, RT was performed to upper and lower
lip clinical target volume with 4 Gy in two fractions, using
two opposite three-dimensional conformal 6-MV photons
beam fields (Fig. 2A and B). The treatment was well toler-
ated, with mild erythema and oral mucositis. After 2 months
from the end of RT, at the first follow-up evaluation, the
patient achieved complete resolution of the tumor. RT tox-
icity was also completely resolved. The patient was submit-
ted to follow-up visits with hematologists and radiation
oncologists and to blood tests every 3 months. At the last
examination performed in December 2017, persistent com-
plete response was recorded.Discussion
Most lymphomas arising from the head and neck region are


















Fig. 1 Immunophenotype of patient (all pictures were taken with a 20 zoom). (A) Hematoxylin–eosin shows the growth pattern;
(B) the diffuse positivity of CD20 B cells; (C) the accompanying T lymphocytes CD3+; (D) CD5 positivity in the T cells and negativity in
the other B cells; (E) CD10 negativity.
Fig. 2 Dose distribution from the radiation treatment plan using two opposite three-dimensional conformal 6-MV photons beam
fields in (A) axial and (B) sagittal computed tomography images.
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2 January 2019Lip region localization of NHL is very rare. In the Tumor
Registry between 1969 and 1998, Epstein et al. [11] identi-
fied only three lip lymphomas among 391 cases in the oral
and paraoral region; up to 2001, another three cases were
reported by Sunaba et al., Yin et al., and Leong et al.
[12–14] Afterwards, in a review of literature performed in
2011 by Shah et al. [15] analyzing extranodal NHL of the oral
cavity, only 7/403 cases involved the lip. Finally, a recentPlease cite this article as: B. Lavinia, S. S. Dario, P. Guido et al., Low-do
Case report and literature review, Hematol Oncol Stem Cell Ther, https:analysis and review of English literature aimed to investi-
gate NHL of the lip was published by Kaplan et al. [16]
between 1996 and 2016, only 23 cases were identified,
indeed they defined these lymphomas as ‘‘a rare entity”.
Regarding histology, in their review, extranodal marginal
zone-B-cell MALT cases were predominant (78.2%). Of note,
40.9% of lip lymphomas were associated with Sjogren’s syn-
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2 January 2019patients affected by this disease is 44 times higher than for
the general population [10], and autoimmune diseases in
particular have been associated with higher risk of extran-
odal MZL [17].
Even our patient was diagnosed as having B-cell NHL of
the MZ, reflecting this as the most frequent histological type
among lymphomas of the lip.
The natural history of extranodal MZL is usually indolent.
In recent literature, the 5-year overall survival rate is
reported to be 88.7%, with a median overall survival of
12.6 years [17].
There is no consensus on the optimal systemic treatment
of patients with extranodal marginal zone lymphoma of
mucosa-associated lymphoid tissue.
NHLs of the head and neck can be treated with
chemotherapy, RT, or both. Different chemotherapeutic
schemes have been used: in indolent NHL, the most fre-
quently used chemotherapy schemes consist of chlorambu-
cil with or without prednisolone, whereas aggressive
diseases are treated with cyclophosphamide, vincristine,
and prednisolone.
The final results of IELSG-19 demonstrated that ritux-
imab in combination with chlorambucil demonstrated supe-
rior efficacy in mucosa-associated lymphoid tissue
lymphoma; however, improvements in event-free-survival
and progression-free survival did not translate into longer
overall survival. Therefore, based on these results Zucca
et al. [18] leaves room to consider the use of chlorambucil
alone, but also provides evidence for the use of single agent
rituximab to avoid the toxicity of chemotherapy.
RT alone is usually indicated in localized disease,
whereas higher stages can be treated with a combination
of chemotherapy and RT [15].
Regarding EMZL in particular, given the frequently lim-
ited stage at presentation, a local approach such as RT have
been the main treatment, with excellent outcomes in terms
of efficacy. In 2003 it was reported to lead to complete
response in 99% and 5-year overall survival of 98%.
In patients with advanced-stage disease, watchful wait-
ing can be the treatment of choice in asymptomatic cases
and if there are severe comorbidities. Otherwise,
chemotherapy or chemo-immunotherapy have been usually
prescribed and MZLs are known to be chemo-sensitive
tumors [17]. In these circumstances, RT can be very useful
for palliation of local symptoms.
In previous years, standard RT prescription doses were
usually between 20 Gy and 35 Gy; afterwards, lower doses
were explored and in 1994, Ganem et al published the first
experience of a total dose of 4 Gy in two fractions [15]. In
that study, 27 patients affected by low-grade NHL were ana-
lyzed, the majority had advanced-stage disease. An objec-
tive response was observed in 24/27 cases, 37% and 52%
had complete and partial responses, respectively. Further-
more, 8/27 responsive to the first course were submitted
to at least another course of low-dose RT [19]. Other
authors have subsequently reported on low-dose RT in
patients affected by advanced indolent NHL, with response
rates ranging from 81% to 92%. In 2012, Russo et al. [21]
retrospectively reviewed 127 patients with NHL submitted
to low-dose RT (4 Gy/2 fr); the total number of sites treated
were 187. The overall response rate was 82%, with 57% cases
of complete and 25% cases of partial response, respectively.Please cite this article as: B. Lavinia, S. S. Dario, P. Guido et al., Low-do
Case report and literature review, Hematol Oncol Stem Cell Ther, https:There was no association between tumor size, site, age at
diagnosis, or the use of previous chemotherapy and
response. On the contrary, histology seemed to be the most
significant factor in predicting response to treatment; in
their clinical records, chronic lymphocytic leukemia was
the only type to be associated with response. Therefore,
the authors concluded that low-dose involved-field RT
should be considered a palliative treatment option in
patients with NHL [21].
In 2014, Hoskin et al. [22] published a randomized,
unblinded, Phase III trial comparing standard dose of 24 Gy
in 12 fractions to lower dose of 4 Gy in two fractions: 614
sites were treated from 2006 to 2011 in patients affected
by follicular or MZL: 81% sites treated with 4 Gy had a com-
plete or partial response compared with 91% in the group
treated with 24 Gy, and progressive disease was reported
in more patients treated with low-dose RT. In the low-
dose RT group, complete remission was observed in >40%
of sites and, as the authors stated ‘‘that a dose as low as
4 Gy can achieve responses in a significant proportion of
the populations remains remarkable”; furthermore, the
incidence of acute Grade 3 or higher toxicity in the group
treated with 4 Gy was approximately half in comparison.
Therefore, they concluded that data supported the use of
4 Gy in two fractions for palliative treatment in the case
of patients with poor performance status [22].
The definite explanation of how such a low dose of RT
can be effective has not yet been given. Many studies have
been performed, especially on follicular lymphoma, and
many possible mechanisms of action have been recognized.
Low-dose RT has been shown to induce apoptosis pathways
of lymphoma cells and the correlation between in vitro RT-
induced apoptosis and in vivo effects of 4 Gy RT has been
demonstrated by Dubray et al. [23]. Many genes are
involved in the apoptosis pathway, such as BCL2, P53,
caspase-8, and caspase-9 [22]. Furthermore, low-dose RT
was reported to induce up-regulation of macrophage
activation-related genes and this activation of macrophages
has been suggested to be subsequent to lymphoma cell
apoptosis and so indirectly related to low-dose RT [24].
Reviewing literature, there are a few aspects of our case
report that deserve attention: firstly, among cases of lym-
phoma of the lip, which has been defined as a ‘‘rare entity”
by others, the diagnosis of our patient was B-cell NHL of the
MZ and so it was even more peculiar. In literature there is
evidence of the effectiveness of low-dose RT in indolent
lymphoma, but experiences of this approach performed in
head and neck extranodal NHLs are very rare. Indeed, to
our knowledge, the largest body of clinical data was
reported by Pinnix et al. [25] who reviewed 22 patients
affected by ocular adnexal B-cell lymphoma treated with
4 Gy RT. Therefore, this may be the first case of low-dose
RT in extranodal MZL of the lip.
Secondly, low-dose RT has been primarily performed in
the palliative setting, as it allows palliation of symptoms
with a short duration of treatment, a very low risk of toxic-
ity, and low cost of therapy, postponing the need for other
approaches [25]. Furthermore, the total RT dose being
extremely low, it can be repeated subsequently in case of
recurrence. Despite this, our patient had localized disease
and so he was treated with a radical intent rather than in
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Please cite this article as: B. Lavinia, S. S. Dario, P. Guido et al., Low-do
Case report and literature review, Hematol Oncol Stem Cell Ther, https:considering the age of our patient and the risk of toxicity
related to different therapies such as chemotherapy or
higher dose RT, low-dose RT seemed to be the preferable
approach.
In literature, evidence of low-dose RT in a definitive set-
ting is lacking: in the FORT trial, 40% of cases were treated
with curative intent and in fact in those patients, 4 Gy was
inferior in terms of local progression compared to higher
doses of 24 Gy [22]. In most other studies, low-dose RT
has been prescribed in patients with advanced or recurrent
disease and in palliative settings [20,21,26]. Therefore, in
our opinion, it would be interesting to perform clinical trials
to investigate efficacy of low-dose RT as radical treatment.
Several experiences with low dose radiation for MZL are










Extranodal MZL of the lip is an extremely rare neoplasm. In
the case of localized disease, RT is an appropriate treat-
ment. The case we have reported shows that in patients
with comorbidities or poor performance status, low-dose
RT can be an appropriate approach with excellent outcomes
in terms of effectiveness. Our patient had a complete
response to treatment with extremely low acute toxicity
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